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Abstract 
Background: A clinical case of an elderly patient with gastroesophageal reflux disease (GERD) 
prompted research of proton pump inhibitor (PPI) use in older adults.  PPIs are one of the top 
prescribed medication classes among the elderly population.  PPIs have generally been 
considered safe but current research has found association between PPI use with multiple 
adverse effects.   
Case Description: An 88-year-old female patient was seen by her primary care provider for a 
chief complaint of cough that persisted for 3 months.  Her symptoms, history, and physical 
assessment were consistent with moderate GERD and she was prescribed low-dose omeprazole 
with intent to follow-up with her provider in 1 month. 
Literature Review: Multiple studies, systematic reviews, and meta-analyses were examined to 
determine risks associated with prolonged PPI use in the elderly population.  Adverse effects 
including dementia, bone fracture, and Clostridium difficile (C. diff) susceptibility were 
discovered.  Also, research found that PPIs are often inappropriately prescribed due to improper 
indication and/or follow-up by providers. 
Clinical Relevance: Provider awareness of PPI misuse may result in the reduction of 
unfavorable clinical outcomes in older adults and promote appropriate PPI prescriptive practice.  
Avoiding adverse drug effects in the elderly population will improve patient health and minimize 
unnecessary healthcare costs. 
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Background 
 E.L., an 88-year-old female, presented to her primary care clinic for complaint of 
persistent cough over three months despite completing treatment for bronchitis.  Her cough was 
dry and nonproductive and typically worsened after eating and laying down at night.  In addition 
to her cough, the patient reported daily heartburn which required frequent treatment with over-
the-counter (OTC) antacids.  The patient’s subjective and objective assessment findings were 
consistent with the diagnostic criteria for gastroesophageal reflux disease (GERD).  She was 
given lifestyle modification instructions and prescribed omeprazole 20 mg by mouth daily with 
plans to follow-up with her provider in one month.   
 Proton pump inhibitors (PPIs), like omeprazole, are among the top 10 most frequently 
prescribed therapeutic drug classes in the United States (Masclee, Sturkenboom, & Kuipers, 
2014).  Elderly patients aged 65 and greater represent the largest consumer group of PPIs and 
most other drug classes (Hamzat et al., 2012).  Additionally, one-third of older adults take more 
than 5 prescribed medications and nearly 20% are prescribed more than 10 (Kennedy-Malone, 
Fletcher, & Martin-Plank, 2014).  Polypharmacy is a primary predictor for adverse drug 
reactions which account for 10% of all emergency room visits and up to 17% of all hospital 
admissions (Kennedy-Malone et al., 2014).  Furthermore, age-related physiologic changes within 
older adults make them prone to adverse drug reactions (Kennedy-Malone et al., 2014).  
Knowing this, providers should exercise caution when introducing new medications to this 
population and intend to prescribe the lowest dose with the shortest duration to achieve 
therapeutic effect.    
For many years PPIs were generally regarded as safe medications with very few adverse 
effects.  However, current research has associated dementia, bone fracture, vitamin and mineral 
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deficiencies, and susceptibility to Clostridium difficile (C. diff) infections with prolonged PPI use 
(Wijarnpreecha et al., 2016).  Furthermore, several studies have determined that over 50% of PPI 
prescriptions are inappropriate or require deprescribing (Bergamo et al., 2015).  The purpose of 
this report is to bring awareness to providers regarding potential adverse effects of prolonged PPI 
use, proper prescribing of PPIs, and deprescribing initiatives in the elderly.  Appropriately 
balancing the indication, benefits, and harms of PPI therapy within this population can 
significantly minimize avoidable adverse effects, morbidity, hospital admission, and healthcare 
costs (Masclee et al., 2014).      
Case Report 
 The following is the report of E.L.’s clinic visit that occurred on Friday, March 10, 2017 
at the University of North Dakota’s New School of Medicine & Health Sciences building.   
Vital Signs: 
Temperature – 97.8° F 
Pulse – 76  
Respirations – 16  
Blood pressure – 130/80 mmHg 
 
Chief complaint: “Cough that won’t go away” 
 
History of Presenting Illness:  
This 88-year-old woman presents to the clinic with a chief complaint of a “cough that 
won’t go away.”  The patient states that the cough began approximately 3 months ago and has 
persisted despite being treated for bronchitis 2 months ago.  The cough is dry, nonproductive, 
and is typically worse at nighttime when she lays down.   The patient also notes that her cough is 
worse after eating or drinking.  To treat the cough, she sleeps with a humidifier in her bedroom 
and sucks on throat lozenges throughout the day.  However, these efforts have provided little to 
no relief.  The patient denies pain or sore throat with her cough.   
She is currently prescribed Lisinopril for hypertension, she is unsure when it was initially 
prescribed to her but states that she has been taking it for “a long time.”  Also, she takes an over-
the-counter antacid several times a day for post-meal heartburn.      
 
Past Medical & Surgical History:  
Essential (primary) hypertension – unknown date of diagnosis  
Abdominal hernia – monitored by gastroenterology  
Denies surgical history 
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Current Medications: 
Lisinopril 10 mg PO daily 
Tums 2-4 tabs PO PRN with meals 
 
Allergies: 
No known drug allergies 
 
Family History: 
Positive immediate family history for heart disease, diabetes, and colon cancer – unknown 
specificity of diseases to family member  
 
Personal & Social History: 
Former smoker 
Consumes 1-2 alcoholic beverages nightly 
Denies illicit drug use 
Consumes 1 pot of coffee (8-12 servings) daily  
Received influenza immunization this season – current on all other immunizations 
 
Review of Systems: 
General – denies fever, chills, night sweats, fatigue, and unintentional changes in body weight 
HEENT – denies headache, sinus pressure, changes in vision or hearing, ear pain, nasal 
discharge, and sore throat 
Cardiac – denies chest pain or pressure, palpitations, and swelling in extremities  
Respiratory – persistent, dry, & nonproductive cough; denies shortness of breath and dyspnea 
Gastrointestinal – heartburn daily with meals; denies abdominal/pelvic pain, nausea/vomiting, 
constipation/diarrhea, hematuria, blood in stool, incontinence, and difficulty voiding 
 
Physical Exam: 
General – well appearing, alert and oriented x3, normal mood and affect 
Head – normocephalic, atraumatic, no pain in frontal or maxillary sinuses with palpation 
Eyes – conjunctiva clear, sclera non-icteric, EOM intact, PERRLA 
Ears – EACs clear, TMs translucent, normal light reflex, ossicles normal appearance     
Nose – no external lesions, mucosa non-inflamed, septum and turbinates normal, no discharge 
Mouth/Pharynx – mucous membranes moist, no mucosal lesions, no redness, no tonsillar 
hypertrophy, no post-nasal drip 
Neck – supple without lymphadenopathy  
Heart – regular rate and rhythm, no murmur, no extra heart sounds, no rubs, no gallops 
Lungs – clear and equal to auscultation without wheeze, rales, or rhonchi bilaterally 
Abdomen – obese with soft, protruding, & reducible hernia in center of abdomen above 
umbilicus; abdomen soft and non-distended, bowel sounds active in all quadrants, no tenderness 
with palpation, no masses, no liver or spleen enlargement    
 
Additional Laboratory Tests, Imaging, and/or Diagnostic Studies: 
No additional studies necessary at this time  
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Assessment/Diagnosis: 
Gastroesophageal reflux disease (GERD)  
 
Plan/Treatment: 
1. Recommended the following lifestyle changes for prevention and treatment of GERD: 
(Dunphy et al., 2015) 
a. Elevate the head of the bed 6-8 inches when laying down 
b. Avoid high-fat meals, large meals, and problematic foods such as chocolate, 
alcohol, peppermint, caffeine, onions, citrus, and tomatoes 
c. Avoid sleeping for 3-4 hours after a meal and avoid bedtime snacks 
d. Weight loss as tolerated 
2. Continue use of OTC Tums 2-4 tabs by mouth as needed for heartburn post meals  
3. Start omeprazole 20 mg by mouth daily on an empty stomach 
4. Follow-up in 1 month for reevaluation.  Follow-up encouraged sooner for worsening 
symptoms or additional questions and concerns.   
 
The common symptoms of GERD are heartburn, regurgitation, dysphagia, coughing, 
hoarseness, and nocturnal wheezing (Dunphy et al., 2015).  Factors that exacerbate symptoms 
include consuming trigger foods such as alcohol or caffeine, reclining after eating, and 
aggravating body positions like heavy lifting or bending over (Dunphy et al., 2015).  The 
physical examination of GERD patients is usually normal and in 80% of cases the diagnosis is 
made by history alone with no required laboratory tests or imaging (Dunphy et al., 2015).  
Therefore, the diagnosis of GERD for E.L. is appropriate based on her reported history and 
negative physical assessment. 
E.L. has daily and persistent symptoms despite regular use of antacids.  Step-up treatment 
for persistent GERD include diet and lifestyle modifications and daily pharmacological therapy 
with an H₂ receptor agonist (H₂RA) or low-dose PPI (Dunphy et al., 2015).  These interventions 
should be trialed for 8 weeks and then reevaluated to determine if step-down therapy is 
appropriate (Dunphy et al., 2015).  Since GERD is a new diagnosis for E.L., her provider will 
follow-up with her in 1 month to monitor her progress.       
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Literature Review 
 The prescription of omeprazole within this case report provoked research of adverse 
effects associated with prolonged PPI use in the elderly as well as appropriate prescribing and 
management of PPIs in this population.  Since PPIs are among the most commonly prescribed 
medications in the United States, a thorough understanding of these topics are necessary for 
providers to effectively balance the indication, benefits, and harms of PPI use.   
Indications for PPIs  
 According to Woo and Robinson (2016), “PPIs are indicated for erosive gastritis, GERD, 
and Zollinger-Ellison syndrome and as part of a multidrug regimen for short-term treatment of 
active peptic ulcer disease (PUD), especially duodenal ulcers caused by Helicobacter pylori” (p. 
528).  For treatment of uncomplicated gastric ulcers, a once daily dose of a PPI is indicated for 
12 weeks (Woo & Robinson, 2016).  In GERD management, PPIs are typically indicated once 
daily for 8 weeks and only after lifestyle modifications and OTC antacids or H₂RAs have been 
trialed (Woo & Robinson, 2016).  PPI treatment is also appropriate for individuals with chronic 
NSAID use or antiplatelet therapy with low-dose aspirin or clopidogrel (Bergamo et al., 2015).  
Long-term PPI use is only recommended in patients with high risk of gastrointestinal bleeding, 
Barrett’s esophagus, or Zollinger-Ellison syndrome (Wilsdon et al., 2017). 
Inappropriate Use of PPIs in the Elderly 
Inappropriate PPI use is determined when patients are prescribed PPIs for indications not 
listed above or for a prolonged period of time.  Multiple reviews have observed inappropriate 
PPI prescription in 50-80% of patients admitted to and discharged from geriatric medicine wards 
(Masclee et al., 2014).  One study observed inappropriate continuation of PPIs in 67% of elderly 
patients after in-hospital initiation for stress ulcer prophylaxis (Wilsdon et al., 2017).  Another 
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study observed that 50-60% of patients became chronic PPI users after treatment of H. pylori 
(Masclee et al., 2014).  Both studies display unsuitable use of PPIs due to lack of proper follow-
up and/or deprescribing initiatives by providers.  
 Another cause for inappropriate PPI prescription in the elderly is seen in patients with 
dementia history.  In one study, 61% of the patient sample with dementia were inappropriately 
prescribed PPIs (Hamzat et al., 2012).  Significant cognitive impairment in this population may 
reduce their ability to properly describe their medical history and reduce a provider’s ability to 
properly diagnose and treat (Hamzat et al., 2012).   
Adverse Effects of Long-term PPI Use 
 Since their introduction to the market PPIs have been regarded as safe and effective 
medications with very few side effects.  Mild adverse reactions such as nausea, abdominal pain, 
constipation, and diarrhea are most frequently reported but mounting evidence demonstrates that 
PPIs may be associated with more severe effects when overprescribed (Pastorino et al., 2015).  In 
fact, the Food and Drug Administration (FDA) has issued several warnings within the last seven 
years regarding long-term PPI use.   
In 2010 a change in labeling information for PPIs was indicated for warning of possible 
increased fracture risk with long-term use (Masclee et al., 2014).  In 2011 the FDA stated that 
PPIs may cause low serum magnesium levels if taken for prolonged periods of time and 
providers should consider monitoring magnesium levels before and during treatment (Pastorino 
et al., 2015).  Most recently, the FDA published a safety alert cautioning the association of PPIs 
and C. diff infection in 2015 (Schoenfeld & Grady, 2016).  
Dementia. In the last 10 to 15 years, numerous studies developed to determine the 
association with prolonged PPI use and dementia prevalence.  Dementia is one of the major 
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disabilities among older adults and is characterized by cumulative cognitive decline and a 
progressive inability to live independently (Gomm et al., 2016).  In 2015, worldwide healthcare 
costs associated with dementia rose to an estimated $818 billion from $604 billion in 2010 
(Batchelor et al., 2017).  Today, 46.8 million people worldwide have dementia and this figure is 
expected to triple by the year 2050 (Batchelor et al., 2017). 
PPIs are hypothesized to cause a decline in cognitive functioning through several 
mechanisms.   First, in vitro studies have shown that PPIs may interfere with degradation of 
amyloid beta (Αβ) peptides resulting in increased Αβ levels, a pathological hallmark of 
Alzheimer’s disease (Wijarnpreecha et al., 2016).  Additionally, PPIs may inhibit lysosomal 
acidification resulting in accumulation of protein aggregates causing vascular dysfunction and a 
potential starting point for cognitive decline (Batchelor et al., 2017).  Finally, presence of 
vitamin B₁₂ deficiency is frequently reported in previous and current PPI users (Gomm et al., 
2016).  “Poor vitamin B₁₂ status has been described as negatively affecting cognition and 
promoting neurological damage, probably owing to impaired DNA synthesis, methylation, and 
homocysteine neurotoxicity” (Gomm et al., 2016, p. 414).  Chronic PPI use has been linked to a 
46% decline in median serum B₁₂ levels and subnormal B₁₂ levels in 10% of patients (Abraham, 
2012).  
The most significant study associating PPI use with dementia examined data from the 
largest German public health insurer covering one-third of the population (Gomm et al., 2016).  
The study found statistically significant data associating prolonged PPI use with increased risk of 
dementia in older adults age 75 and above (Gomm et al., 2016).  A similar study used detailed 
neuropsychological tests to establish the diagnosis of dementia and found a 1.4-fold increased 
risk of any dementia in cohorts using PPIs (Batchelor et al., 2017).  Also, a meta-analysis found 
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a small but elevated risk of dementia among PPI users but it was not statistically significant 
(Wijarnpreecha et al., 2016).    
Bone Fracture. Older adults, especially elderly women, are at increased risk of bone 
degeneration and fracture due to hormonal and other physiological age-related changes.  
Efficient calcium absorption is essential for skeletal integrity but research has found that 
prolonged PPI use may be associated with decreased calcium absorption (Hinson et al., 2015).  
Prolonged PPI use has been linked to PPI-induced hypochlorhydria which causes impaired 
calcium absorption and reduced calcium bioavailability (Hinson et al., 2015).  Hypochlorhydria 
results in compensatory and chronic hyperparathyroidism leading to increased bone turnover 
(Hinson et al., 2015). 
 A systematic review evaluated 4 studies that discovered modest association between 
high-dose PPI use and fractures of the hip, spine, wrist, and forearms (Hinson et al., 2015).  
Individuals aged 50 and older who used PPIs for 1 year or longer were at greatest risk of fracture 
(Hinson et al., 2015).  Also, a meta-analysis of 18 observational studies found that PPI use was 
associated with a 26% higher risk of hip fracture, a 58% higher risk of spine fracture, and a 33% 
higher risk for fracture at any site (Schoenfeld & Grady, 2016).  No studies have proven 
association between long-term PPI use and low bone mineral density (BMD) but BMD findings 
alone are not sufficient evidence to dismiss association of PPIs and fracture risk (Hinson et al., 
2015). 
Clostridium difficile Susceptibility. Perhaps the most widely accepted data regarding 
adverse effects from prolonged PPI use is found with C. diff susceptibility.  Stomach acid 
provides a natural defense against microbial pathogens but PPIs cause a reduction in gastric 
acidity (Woo & Robinson, 2016).  Reduction in gastric acidity may promote bacterial 
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overgrowth in the gastrointestinal tract thus increasing the risk of C. diff infection (Schoenfeld & 
Grady, 2016).  Also, bacterial overgrowth and colonization within the small intestine can result 
in malabsorption of fat, carbohydrate, protein, and micronutrients leading to diarrhea and 
malnutrition (Teramura-Grönblad et al., 2010).  Individuals that acquire C. diff, a toxin-
producing pathogen that is damaging to the bowel mucosa, often require hospital management 
for dehydration and/or malnutrition and have prolonged hospital stays (Dunphy et al., 2015). 
 One meta-analysis of 5 studies found that C. diff-associated diarrhea in elderly PPI users 
also on broad spectrum antibiotics increased 2- to 3-fold (Abraham, 2012).  A more recent meta-
analysis of 39 studies mirrored these findings and determined a 74% higher risk of developing C. 
diff infection and a 2.5-fold higher risk of reoccurring C. diff infection among PPI users versus 
nonusers (Schoenfeld & Grady, 2016).   
Another study found elderly nursing home patients on PPIs had 19.7% increased 
incidence of diarrhea than nonusers (Teramura-Grönblad et al., 2010).  Diarrhea is often 
considered a mild medication side effect but it cannot be overlooked in nursing home patients.  
“In this frail elderly population dependent on other people’s continuous help, frequent diarrhea is 
a burdensome symptom causing unnecessary suffering and skin problems” (Teramura-Grönblad 
et al., 2010, p. 157).  Other potential complications of diarrhea include dehydration, malnutrition, 
peritonitis, sepsis, shock, anemia, and/or electrolyte imbalances (Kennedy-Malone et al., 2014).  
Implications for Practice 
 Unfortunately, research regarding adverse effects of prolonged PPI use in the elderly 
population is preliminary and results are varied or inconsistent.  The results are commonly 
critiqued and questioned due to suspicion of bias, disregard for comorbidities and/or 
comedications, lack of ethnic diversity, or inconsistent diagnostic tools.  Thus, no new practice 
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guidelines regarding safe PPI prescription in the elderly have been prompted from these studies.  
 Nonetheless, providers should be cognizant of these potential adverse effects and utilize 
every opportunity to evaluate appropriate indication of use of PPIs.  Batchelor et al. (2017) 
suggests that “meticulous risk-benefit analysis when prescribing PPIs should be considered in all 
cases, especially among older patient populations” (p. 17).  Furthermore, deprescribing of PPIs 
should be initiated whenever clinically appropriate. 
 Deprescribing is the process of withdrawing an inappropriate medication with the goal to 
manage burdens of medication and improve outcomes (Wilsdon et al., 2017).  For example, a 
step-down approach to an OTC H₂RA should be initiated after 8 weeks of PPI therapy in patients 
with moderate GERD (Woo & Robinson, 2016).  However, there are several barriers to 
deprescribing PPIs including concern for return of symptoms, lack of patient knowledge of 
deprescribing necessity, and lack of provider initiation (Wilsdon et al., 2017).   
 Wilsdon et al. (2017) conducted a systematic review of 21 studies to evaluate effective 
strategies for deprescribing inappropriate PPIs in older adults.  Strategies included nationwide 
public educational campaigns, pharmacist-led interventions, distribution of educational 
brochures to patients, and education seminars for hospital clinicians.  Many approaches were 
successful at decreasing inappropriate PPI prescriptions but in the end, the authors recommended 
that healthcare providers utilize a common-sense approach when reviewing patient medications 
(Wilsdon et al., 2017).  Ultimately, it is the provider’s responsibility to be familiar with potential 
adverse effects associated with prolonged PPI use and to be vigilant in their prescribing habits 
(Abraham, 2012). 
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Learning Points 
 In conclusion, chronic use of PPIs in the elderly population has caused uncertainty 
regarding potential adverse effects associated with their long-term or inappropriate use.  Multiple 
risks have been linked to prolonged PPI use and greater attention must be paid to protect older 
adults from unnecessary harm and to cut healthcare costs (Bergamo et al., 2015).  Providers 
should consider the following facts when prescribing PPIs:   
• The elderly population represents the largest group of consumers of PPIs and other 
medications.  Also, they have an elevated risk for adverse drug reactions resulting in 
hospital admissions and increased healthcare expenditures.     
• The use of PPIs in older adults is often prolonged or unnecessary due to inappropriate 
prescribing and/or monitoring by providers.   
• Overuse of PPIs has been linked to multiple adverse effects in the elderly population 
including dementia, bone fracture, and C. diff susceptibility.  Unfortunately, studies 
regarding these effects are inconsistent so no changes in practice have been warranted at 
this time.  
• It is the provider’s responsibility to recognize the potential risks associated with 
prolonged PPI use.  They must exercise caution when prescribing PPIs to the elderly and 
ensure proper indication and follow-up to prevent misuse.   
Providers should discuss the potential benefits and risks of PPI use with each patient and 
individualize treatment to achieve optimal clinical outcomes.  With this practice and 
acknowledgement of the facts listed above, PPI-related adverse effects in the elderly population 
may be reduced significantly and unnecessary burdens on the healthcare system avoided. 
 
PPI USE IN THE ELDERLY  15 
 
References 
Abraham, N.S. (2012). Proton pump inhibitors: Potential adverse effects. Current Opinion 
 Gastroenterology, 28(6), 615-620. 
Batchelor, R., Gilmartin, J.F.M., Kemp, W., Hopper, I., & Liew, D. (2017). Dementia, cognitive 
 impairment and proton pump inhibitor therapy – A systematic review. Journal of 
 Gastroenterology and Hepatology. doi: 10.1111/jgh.13750 
Bergamo, D., Pastorino, A., Greppi, F., Versino, E., Bo, M., D’Amelio, …E., Isaia, G. (2015). 
 Inappropriate proton pump inhibitor prescription in elderly adults: As usual as dangerous. 
 Journal of the American Geriatrics Society, 63(10), 2198-2199. 
Dunphy, L.M., Winland-Brown, J.E., Porter, B.O., & Thomas, D.J. (2015). Primary care: The 
 art and science of advanced practice nursing (4th ed.). Philadelphia, PA: F.A. Davis 
 Company. 
Gomm, W., von Holt, K., Thomé, F., Broich, K., Maier, W., Fink, A., …Haenisch, B. (2016). 
 Association of proton pump inhibitors with risk of dementia a pharmacoepidemiological 
 claims data analysis. Journal of American Medical Association Neurology, 73(4), 410-
 416. 
Hamzat, H., Sun, H., Ford, J.C., MacLeod, J., Soiza, R.L., & Mangoni, A.A. (2012). 
 Inappropriate prescribing of proton pump inhibitors in older patients. Drugs Aging, 29(8), 
 681-690. 
Hinson, A.M., Wilkerson, B.M., Rothman-Fitts, I., Riggs, A.T., Stack Jr., B.C., & Bodenner, 
 D.L. (2015). Hyperparathyroidism associated with long-term proton pump inhibitors 
 independent of concurrent bisphosphonate therapy in elderly adults. Journal of the 
 American Geriatrics Society, 63(10), 2070-2073. 
PPI USE IN THE ELDERLY  16 
 
Kennedy-Malone, L., Fletcher, K.R., & Martin-Plank, L. (2014). Advanced practice nursing in 
 the care of older adults. Philadelphia, PA: F.A. Davis Company. 
Masclee, G.M.C., Sturkenboom, M.C.J.M., & Kuipers, E.J. (2014). A benefit-risk assessment of 
 the use of proton pump inhibitors in the elderly. Drugs Aging, 2014(31), 263-282. 
Pastorino, A., Greppi, F., Bergamo, D., Versino, E., Bo, M., Pezzilli, M.S., …Isaia, G. (2015). 
 Proton pump inhibitors and hypomagnesemia in polymorbid elderly adults. Journal of the 
 American Geriatrics Society, 63(1), 179-180. 
Schoenfeld, A.J. & Grady, D. (2016). Adverse effects associated with proton pump inhibitors. 
 Journal of the American Medical Association Internal Medicine, 176(2), 172-174. 
Teramura-Grönblad, M., Hosia-Randell, H., Muurinen, S., & Pitkala, K. (2010). Use of proton-
 pump inhibitors and their associated risks among frail elderly nursing home residents. 
 Scandinavian Journal of Primary Health Care, 2010(28), 154-159. 
Wijarnpreecha, K., Thongprayoon, C., Panjawatanan, P., & Ungprasert, P. (2016). Proton pump 
 inhibitors and risk of dementia. Annals of Transitional Medicine, 4(12), 240-245. 
Wilsdon, T.D., Hendrix, I., Thynne, T.R.J., & Mangoni, A.A. (2017). Effectiveness of 
 interventions to deprescribe inappropriate proton pump inhibitors in older adults. Drugs 
 Aging, 2017(34), 265-287. 
Woo, T.M. & Robinson, M.V. (2016). Pharmacotherapeutics for advanced practice nurse 
 prescribers (4th ed.). Philadelphia, PA: F.A. Davis Company. 
 
 
